Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,816 people get SPPI articles and Market Currents by email alert.
Get email alerts on SPPI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Business Wire (May 9, 2013)
-
Business Wire (May 2, 2013)
-
-
-
-
-
PR Newswire (Mar 21, 2013)
-
-
Business Wire (Mar 18, 2013)
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
Business Wire (May 9, 2013)
-
Business Wire (May 2, 2013)
-
PR Newswire (Mar 21, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 14, 2013)
-
at MarketWatch.com (Mar 13, 2013)
-
at MarketWatch.com (Mar 12, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Feb 12, 2013)
-
Business Wire (Jan 17, 2013)
SPPI vs. ETF Alternatives
Company Description
Overview
We are a commercial stage biopharmaceutical company committed to developing and commercializing innovative therapies with a focus primarily in the areas of hematology-oncology and urology. We have a fully developed commercial infrastructure that is responsible for the sales and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 13, 3:56 PM The 25 most heavily shorted stocks (as a percent of float) in the S&P 1500 as of the end of April are up 6.75% in May, trouncing the S&P's 2.33% gain, according to Bespoke - and this doesn't include Tesla, up 57% with 40% of its float shorted, but not a S&P 1500 member. The top 5 heavily shorted: BTH, QCOR, CSTR, BRLI, SPPI. The rest in another post. 4 Comments
- Thursday, May 9, 7:55 AM Spectrum (SPPI): Q1 EPS of -$0.05 beats by $0.11. Revenue of $38.7M beats by $2.28M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, March 14, 8:31 AM Spectrum (SPPI +2.2%) signs a licensing and supply deal with Ligand (LGND) for the latter's Captisol-enabled melphalan for use in multiple myeloma transplant programs. Spectrum will pay $3M upfront, over $50M in milestones and then royalties. Ligand also raises its guidance and now expects 2013 EPS of $0.47-0.51 vs consensus of $0.36 and revenues of $43-46M vs $43.2M. For Q1, Ligand predicts EPS of $0.10-0.13 vs -$0.01 and revenues of $10-11M vs $8.04M. (PR) Comment! [Healthcare, Earnings]
-
Wednesday, March 13, 9:10 AM
Premarket gainers: BGMD +15%. SUMR +10%. PPHM +5%.
Losers: SPPI -36%. VELT -32%. ASMI -13%. EXPR -13%. TEU -10%. DOLE -7%. WFR -6%. Comment! [On the Move] - Wednesday, March 13, 8:30 AM Spectrum Pharmaceuticals (SPPI) collapses 35% after it yesterday forecast FY 2013 revenues of $160-180M, well below consensus of $297M, due to weak sales of its Fusilev treatment. "Fusilev is Spectrum's biggest and most important drug, so its demise can't be made up elsewhere," writes The Street's Adam Feuerstein. 2 Comments [Healthcare, On the Move]
-
Tuesday, March 12, 5:48 PM
After-hours top gainers, as of 5:15 p.m.: XNPT +11%. DTSI +8%. ARQL +8%. SGMS +7%. EVER +7%.
After-hours top losers: SPPI -35%. VELT -26%. KTOS -16%. MUX -8%. TEU -8%. 3 Comments [On the Move] - Tuesday, March 12, 4:44 PM Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. 14 Comments [Healthcare, Earnings]
- Thursday, February 21, 7:20 AM Spectrum Pharmaceuticals (SPPI): Q4 EPS of $0.27 beats by $0.01. Revenue of $70.1M beats by $0.22M. (PR) 9 Comments [Earnings, Breaking News, Healthcare]
- Tuesday, January 29, 4:02 PM Spectrum Pharmaceuticals (SPPI +4.6%) finishes the day higher after saying late yesterday that safety findings from its Phase 2 trial of belinostat showed an acceptable profile in patients with relapsed T-cell lymphoma. 5 Comments [Healthcare, On the Move]
- Monday, January 28, 2:00 PM Spectrum Pharmaceuticals (SPPI -1.5%) slips after releasing safety findings from its Phase 2 BELIEF trial of belinostat, a pan-histone deacetylase inhibitor. The trial showed the drug had an acceptable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma, including patients who have received a previous allogeneic or autologous stem cell transplant. SPPI says an NDA filing is expected by mid-2013, and an FDA decision in 2014. 3 Comments [Healthcare, On the Move]
- Tuesday, January 15, 3:18 PM Shares of Spectrum Pharmaceuticals (SPPI -0.7%) slip after Credit Suisse initiated the shares with a tepid Neutral rating ealier this morning. The firm says its concerned about the impact of increased competition from Leucovorin, which is a generic SPPI's Fusilev. Sales of Fusilev may decrease from 2012 highs and limit near-term stock performance, and Credit Suisse feels it's more prudent to take a wait-and-see approach and look to buy SPPI once there's greater visibility. 6 Comments [Healthcare]
- Friday, January 11, 3:17 PM Spectrum Pharmaceuticals (SPPI -2.4%) says it's promoted Joseph Turgeon to chief commercial officer. He will be responsible for global commercial and sales activities and will report to the company's COO, Ken Keller. The company adds that it's completed the strategic strengthening of its sales force in the U.S., adding 60 sales professionals in an effort to ramp up the marketing of its oncology products. Comment! [Healthcare]
- Tuesday, December 11, 2012, 7:11 AM Spectrum Pharmaceuticals (SPPI) declares special dividend of $0.15/share quarterly dividend. For shareholders of record Dec. 20. Payable Dec. 28. Ex-div date Dec. 18. (PR) 4 Comments [Dividends]
- Monday, October 29, 2012, 8:42 AM Spectrum Pharmaceuticals (SPPI) names Joseph Turgeon as Senior VP of Sales & Commercial Operations as part of the firm's strategy to expedite growth. Turgeon brings plenty of pharma sales experience, including working for over 20 years at Amgen with Spectrum COO Ken Keller. Meanwhile, Chief Commercial Officer Jim Shields is retiring due to health reasons. (PR) 1 Comment [Healthcare]
- Monday, September 24, 2012, 10:08 AM Spectrum (SPPI -3.1%) is at odds with Danish partner TopoTarget over the results of a Phase II trial for their lymphoma drug belinostat. TopoTarget says the primary endpoint has been met, as the tumors in at least 20% of patients shrank. However, Spectrum is far more cautious, describing the results as "preliminary" and saying that the full outcome won't be known until all the data is analyzed. (PR) 2 Comments [Healthcare, On the Move]
- Friday, August 31, 2012, 3:05 PM Spectrum Pharmaceuticals (SPPI -1%) disclosed in a regulatory filing that it expects pro forma revenue to be $300M by the end of 2012. Additionally, it said the list price for its metastatic colorectal and bone cancer treatment, Fusilev, was increased once in Q1 and again in Q2 of 2012. 8 Comments [Healthcare]
-
- View all 1 replies
-
-
MagicDiligence
Final new stock is Spectrum Pharma $SPPI. Hematology/oncology biotech. Looks like there are lawsuits outstanding here, short ratio 55%. - View all 0 replies
-
- View all 1 replies
-
William LeGro: When they finally came clean about Fusilev, I thought "crooks." Now a class-action. W/current mgmt, I've lost any hope for this company.
-
Michael Webb
$SPPI A.F. Vindicated. As I predicted, Raj (the problem) will leave this year. Spectrum shareholders will profit nicely on sale/rebirth. - View all 5 replies
-
mitrado: AF predicted the Fusilev Bubble would burst 2 years ago, when Fusilev was selling around $20m per quarter... but that doesn't matter. Right?
-
Michael Webb: It does matter. You're right. I made reference to the point taken, not the when of it.
-
VFC's Stock House
Stock Watch Wednesday, 13 March - $SNWV.OB, $SPPI, $IMSC.PK, $BA - http://bit.ly/cAHZ42 - View all 0 replies
-
- View all 2 replies
-
-
William LeGro: Isn't that kind of lying illegal? Obviously he knew what was happening long before he told anyone, and still he lied. Isn't that SEC stuff?
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Retail Investor
$SPPI $AMRN Spectrum Shareholders discussion group started- Pls join >http://bit.ly/Vtxkxx - View all 5 replies
-
mitrado: I was confident in this company but now I feel cheated. The CEO hurt the company a lot more than shortsellers by lying to investors...
-
Retail Investor: yes I am embarrassed to say I was duped. I just hope people who perpetrated this fraud are brought to books.
LATEST REPLIES
-
- View all 1 replies
-
-
Retail Investor
$SPPI $AMRN Spectrum Shareholders discussion group started- Pls join >http://bit.ly/Vtxkxx - View all 5 replies
-
mitrado: I was confident in this company but now I feel cheated. The CEO hurt the company a lot more than shortsellers by lying to investors...
-
Retail Investor: yes I am embarrassed to say I was duped. I just hope people who perpetrated this fraud are brought to books.
-
- View all 1 replies
-
William LeGro: When they finally came clean about Fusilev, I thought "crooks." Now a class-action. W/current mgmt, I've lost any hope for this company.
-
Brian Nichols
I like what's happening with $SPPI The trend looks to be positive, shorts have been unable to push below $11 - View all 4 replies
-
Nahodny Okoloiduci: actually it was last batch of planned sale, therefore positive impact.. read recent 8k -
mitrado: Know we understand why he sold so many shares. He was lying about Fusilev's growth. I really hope Raj leaves. I can never trust him again.
-
craig thomas
Given up trying to figure out why SPPI trades the way it does...maybe i'll just check back again in 6 month's time and see where we are! - View all 3 replies
-
-
-
Michael Webb
$SPPI A.F. Vindicated. As I predicted, Raj (the problem) will leave this year. Spectrum shareholders will profit nicely on sale/rebirth. - View all 5 replies
-
mitrado: AF predicted the Fusilev Bubble would burst 2 years ago, when Fusilev was selling around $20m per quarter... but that doesn't matter. Right?
-
Michael Webb: It does matter. You're right. I made reference to the point taken, not the when of it.
-
- View all 2 replies
-
-
William LeGro: Isn't that kind of lying illegal? Obviously he knew what was happening long before he told anyone, and still he lied. Isn't that SEC stuff?
-
FortSumter
$SPPI Been long this stock for almost a year. Heavy manipulated but cheap in terms of valuation. Up 10% in last week. Sold May $13.85 --> - View all 1 replies
-
FortSumter: covered calls for $1.30 for the inevitable pullback. If not glad to be rid of. Come one Dam F, take'er down.
-
- View all 3 replies
-
FortSumter: Love your enthusiasm. But waiting for usual AF or Citron rug pull.
-
-
mitrado
$SPPI Adam Feuerstein trolling again: http://bit.ly/Ze3Tm0 | Why does AF keep on lying & misleading investors? http://bit.ly/zcz1QE - View all 1 replies
-
Nahodny Okoloiduci: Mr.Fraudenstein Has Unhealthy Obsession With Spectrum Pharmaceuticals
-
- View all 2 replies
-
-
mitrado: Well, it crashed a month later... I knew it was on the making. Crooks like Adam Feuerstein should all be put in jail for a very long time.
-
- View all 1 replies
-
-
- View all 20 replies
-
-
Cabeza Howe: Absolutely agree. Sizing is critical. Never get overexcited. But this is also a time of opportunities thanks to the politicians.
-
- View all 15 replies
-
-
LEIGHDIST: doesn't mean anything it looks like exercising they rights, regardless good luck i hope it pops for you
-
- View all 4 replies
-
-